Economic Evaluation of Positron Emission Tomography (PET) in Non Small Cell Lung Cancer (NSCLC), CHERE Working Paper 2007/6



The chemotherapy costs were based on the estimation of the costs used by the HTBS
for the use of chemotherapy in advanced disease (stage III and IV) NSCLC. The chemotherapy
cost was estimated for Cisplatin plus Vinorelbine but using Australian data. The cost
estimation can be seen in Appendix 1. This took data from the Pharmaceutical Benefit
Schedule for Cisplatin and Vinorelbine. The inpatient and outpatient costs were taken from the
literature. A number of assumptions had to be made in calculating the cost with the costs of
drug preparation and administration, side effects and counselling costs all having to be taken
from the UK costs estimates and transferred into Australian dollars.
39 To take into account the
high uncertainty over the chemotherapy and radiotherapy costs a two way sensitivity analysis
will be undertaken with the values for both costs being doubled and halved.

If N0/1 M0 patients correctly underwent surgery and survived then they were assumed to be
free from disease and did not undergo anymore direct costs. Patients will undergo a course of
radiotherapy if they are correctly identified as N2/3 M0 patients, and then followed up with a
course of chemotherapy. It is also assumed that 10% of patients with N2/3 undergoing a futile
thoractomy will be identified as such and progress to radical radiotherapy and chemotherapy.
All other patients that undergo a futile thoractomy are assumed to just undergo chemotherapy
because when the disease reappears it is too late to treat it any other way. Those identified as
having M1 disease will undergo palliative care in the form of chemotherapy.

Discounting Costs and Benefits

The majority of cost occurs immediately after or soon after diagnosis. The only patients
that are likely to be affected are the N0/1 M0 patients whose life expectancy are 4.5 years if
successfully operated upon and will receive post operative follow up costs and terminal care
costs. However, there is no firm data on these costs and any speculation on the make up of
these costs would be speculative, therefore a decision was made not to discount costs and
benefits in this model this is consistent with the HTBS and NICE studies.

39 HTBS, “Comment on NICE Technology Appraisal Guidance on the use of Docetaxel and Paclitaxel ,
Gemcitabine and Vinorelbine for the treatment of non small cell lung cancer” 2001B.

16



More intriguing information

1. The name is absent
2. Personal Experience: A Most Vicious and Limited Circle!? On the Role of Entrepreneurial Experience for Firm Survival
3. Luce Irigaray and divine matter
4. Dynamiques des Entreprises Agroalimentaires (EAA) du Languedoc-Roussillon : évolutions 1998-2003. Programme de recherche PSDR 2001-2006 financé par l'Inra et la Région Languedoc-Roussillon
5. The name is absent
6. Education as a Moral Concept
7. The Cost of Food Safety Technologies in the Meat and Poultry Industries.
8. PROTECTING CONTRACT GROWERS OF BROILER CHICKEN INDUSTRY
9. The effect of classroom diversity on tolerance and participation in England, Sweden and Germany
10. The name is absent
11. The name is absent
12. The name is absent
13. Happiness in Eastern Europe
14. Climate Policy under Sustainable Discounted Utilitarianism
15. The growing importance of risk in financial regulation
16. Reconsidering the value of pupil attitudes to studying post-16: a caution for Paul Croll
17. Studies on association of arbuscular mycorrhizal fungi with gluconacetobacter diazotrophicus and its effect on improvement of sorghum bicolor (L.)
18. The name is absent
19. The name is absent
20. A Bayesian approach to analyze regional elasticities